Sexual differentiation: anatomy, hormones, and response
Trace fetal hormone pathways, compare androgen response with DHT production, and explain puberty using visual models and original clinical practice.
A chromosome result, a hormone concentration, and an anatomical finding answer different questions. Learn to connect them without treating any one as a complete description of a person. Start with the developmental pathways, test a prediction, and then apply the same reasoning to a patient.
Start with the target, not the chromosome label
A teenager has testes, no uterus, and breast development. Before naming a condition, ask what each observation establishes. Testicular tissue identifies the gonad. An absent uterus raises a question about fetal Mullerian development. Breast development records estrogen action. None of those findings alone tells you whether androgen receptors work.
Separate five dimensions: chromosomes and relevant genes; gonadal development; internal ducts; external genital development; and pubertal hormone effects. These dimensions interact, but they are not interchangeable. Gender identity is not a laboratory result and should not be inferred from a karyotype, anatomy, or an educational diagram.
The early gonad can enter different developmental pathways. SRY commonly participates in testicular differentiation, together with other genes. A Y chromosome is therefore useful information, not a guarantee of functioning testes. Conversely, translocated testis-determining material can matter even when a chromosome count reads 46,XX. [11]
Complete 46,XY gonadal dysgenesis makes this distinction concrete. Dysgenetic gonads may provide neither effective fetal AMH nor adequate pubertal sex steroids. A uterus can remain, and spontaneous breast development may be absent. This differs from complete androgen insensitivity, in which testes formed and their AMH can still act. [5]
Think of the workup as inspecting separate components, not selecting a label from appearance. First establish which tissue exists. Then ask whether a hormone is produced, whether it reaches its target, and whether that target responds. A normal blood concentration cannot prove a normal response.
Predict: can a 46,XY result coexist with a uterus?
Yes. Complete gonadal dysgenesis can prevent effective fetal AMH production. AMH or AMH-receptor defects can also preserve Mullerian structures despite testes. The chromosome result alone cannot choose between these mechanisms. [5][6]
Follow two independent fetal pathways
Once testes have differentiated, Sertoli cells and Leydig cells do different jobs. Sertoli-cell AMH acts through the AMH signaling pathway to promote Mullerian duct regression. Those ducts would otherwise contribute to structures including the uterus and fallopian tubes. Leydig-cell testosterone supports Wolffian duct development when androgen signaling is effective. [11]
Testosterone must be formed before it can be converted to DHT. In testicular steroid synthesis, 17-beta-hydroxysteroid dehydrogenase type 3 (HSD17B3) converts androstenedione to testosterone; SRD5A2 then acts on testosterone to form DHT. Specialists interpret testosterone relative to its precursor and its downstream product. These results favor a localization rather than excluding every partial or combined defect. [11]
Testosterone can also be converted to dihydrotestosterone, or DHT, by 5-alpha-reductase type 2 in relevant tissues. DHT acting through the androgen receptor is important for typical masculinization of the external genitalia and prostate. Testosterone and DHT share the androgen receptor; AMH does not use that receptor.
Now interrupt only androgen reception. Testosterone and DHT may be present, but their target response is impaired. AMH can still act independently, so a uterus may be absent. This is why the external appearance in complete androgen insensitivity does not predict retained Mullerian structures. [2]
Instead interrupt only AMH reception. Testosterone and DHT can still act, so external masculinization may be typical while Mullerian structures persist. Persistent Mullerian duct syndrome can involve AMH itself or its receptor, AMHR2. A normal AMH concentration does not rule out failure to respond to that hormone. [6]
Use the pathway model to change one variable at a time. Predict the duct result before changing AMH action. Then change androgen reception while holding AMH constant. The useful observation is what stays the same: disabling androgen reception does not automatically disable Mullerian regression.
This model isolates selected signals. It does not recreate every developmental gene, local tissue interaction, enzyme variant, or mixed gonadal state. Use it to understand dependencies, not to assign a clinical diagnosis from three switches. Real evaluation combines examination, imaging, age-appropriate hormones, and selected genetic testing. [11]
What would supplied DHT test that a testosterone level cannot?
In an appropriate experimental system, supplied DHT bypasses testosterone-to-DHT conversion. A response can show that downstream androgen reception works. Failure despite DHT suggests a downstream problem; it is not proof that the enzyme making DHT is deficient.
Compare a conversion problem with a response problem
Complete androgen insensitivity, or CAIS, is an androgen-response disorder. Testes may produce testosterone, and DHT may also be available, but androgen signaling is ineffective. Breast development can occur because aromatase converts androgen substrates to estrogens and estrogen receptors remain functional. Aromatization is not a special disposal pathway for otherwise unused testosterone. [2][11]
SRD5A2 deficiency is different. The conversion from testosterone to DHT is impaired, but androgen receptors can respond. External genital development before birth can be undervirilized. At puberty, rising testosterone can support voice deepening and phallic growth. The degree and pattern of change vary between people. [3]
Aromatase is a different conversion step. It converts androgen substrates to estrogens; DHT itself is not an aromatase substrate. Placental aromatase normally helps limit fetal androgen exposure reaching the pregnant parent. Aromatase deficiency can connect maternal virilization during pregnancy with inadequate estrogen-driven puberty in a 46,XX child. Inadequate estrogen feedback can increase gonadotropin drive despite the presence of ovarian follicles. [13][18][21]
Do not reduce this distinction to a promise about a beard. Facial hair can remain limited in SRD5A2 deficiency, even when other virilization occurs. Likewise, pubic or axillary hair in CAIS is often sparse, but a hair pattern is not an absolute diagnostic test. It must be read with the hormone and anatomical evidence.
The laboratory question is also conditional. Testosterone and DHT vary with age, pubertal stage, stimulation conditions, and assay performance. A ratio calculated from a DHT value below the assay limit is not a precise biological measurement. Specialist interpretation and appropriate molecular testing can clarify a suspected conversion defect. [11]
A stimulation test asks what a tissue can produce when its signal is supplied. Human chorionic gonadotropin (hCG) acts through the LH receptor on Leydig cells, allowing specialists to assess testicular testosterone production and related precursors or products. Cosyntropin instead supplies an ACTH-like signal to the adrenal cortex. It helps characterize an adrenal steroid-synthesis pattern, such as a borderline 17-hydroxyprogesterone result. The two tests stimulate different tissues and are not interchangeable. [11][12]
Compare the two pubertal profiles in the model. Both begin with effective fetal AMH action and therefore absent Mullerian structures. Change the androgen mechanism, not the chromosome label. Ask which hormone can still produce an effect, and then predict what puberty may reveal.
Later hormone effects do not recreate fetal duct development. Increasing androgen action at puberty may affect responsive tissues, but it does not restore a uterus after fetal Mullerian regression. The time at which a signal acted is part of the explanation, not an optional detail.
Why can normal DHT coexist with little androgen effect?
Adequate hormone production does not prove a responsive target. In CAIS, androgen-receptor dysfunction can prevent the expected effect despite available testosterone and DHT. The relevant failure is response, not necessarily synthesis. [2]
Read the gonad through its feedback signals
A high gonadotropin concentration is not proof that the gonad is working well. It can represent compensation for inadequate feedback. With low estradiol, markedly elevated FSH supports primary gonadal dysfunction. With low estradiol and low or inappropriately normal gonadotropins, think about inadequate central stimulation instead. [1]
Turner syndrome can involve a missing or structurally altered X chromosome, sometimes in a mosaic pattern. Ovarian function is variable: many patients need hormone treatment for puberty, but some have spontaneous pubertal development. Pubic hair can reflect adrenal androgen action and does not prove normal ovarian estrogen production. [7]
Klinefelter syndrome most often involves 47,XXY, with mosaic forms also possible. Small testes, impaired sperm production, and variable testosterone deficiency may appear. Do not call the seminiferous tubules the testosterone factory: Leydig cells produce testosterone; the Sertoli-cell and seminiferous compartment supports spermatogenesis and contributes inhibin B feedback. [8][11]
Low inhibin B helps explain elevated FSH in impaired seminiferous function. Low testicular steroid output helps explain elevated LH. These can occur together, but the measurements report different functions. An infertility case with preserved testosterone can still have substantial impairment of sperm production and inhibin feedback. [19][20]
These feedback pathways overlap: sex steroids also contribute to FSH regulation, especially when inhibin B is low. In a controlled comparison, holding testosterone and estradiol steady helps isolate the effect of lost inhibin feedback. Restoring Sertoli-cell inhibin alone should not be mistaken for restoring Leydig-cell steroid production. [19][20]
Chromosome-associated conditions also require care beyond reproductive symptoms. Turner-associated cardiovascular and renal abnormalities matter even when an adolescent has some breast development. Klinefelter-related care may include endocrine, fertility, bone, and learning support. Neither condition is defined by one universal appearance. [7][8]
Does some breast development exclude Turner syndrome?
No. Residual ovarian function varies, especially with mosaicism. Current pubertal progression and the estradiol-FSH relationship are more informative than an absolute rule that every patient must lack breast development.
A testis-determining gene is not a complete fertility program. A functional SRY region translocated to an X chromosome can initiate testicular development in a 46,XX individual. Other Y-chromosome genes are important for sperm production, so testicular development does not establish preserved spermatogenesis. Hormone production and fertility must be assessed separately. [16][17]
Use the steroid pattern and the patient's stability
Adrenal androgen exposure can alter external genital development without supplying fetal testicular AMH. A 46,XX infant with 21-hydroxylase deficiency can therefore have virilized external genitalia and a uterus. Do not assume that androgen effects must remove Mullerian structures. The two pathways remain separate. [9]
The immediately dangerous question in an ill newborn is not the chromosome label. Vomiting, poor feeding, shock, hypoglycemia, hyponatremia, or hyperkalemia can indicate adrenal crisis. Emergency hydrocortisone, fluid and glucose support, and monitored electrolyte treatment must not wait for genetic confirmation. Other serious neonatal causes, including infection, still need parallel assessment. [12][14][15]
Classic salt-wasting 21-hydroxylase deficiency is not the same as every partial enzyme defect. Nonclassic disease can present later with androgen-related symptoms without neonatal shock. An appropriately obtained early-morning 17-hydroxyprogesterone is a screening tool; borderline results can require a cosyntropin-stimulated adrenocortical profile rather than diagnosis by one number. [12]
Now change the direction of the blood-pressure finding. Low sex steroids with hypertension and hypokalemia raises concern for 17-alpha-hydroxylase/17,20-lyase deficiency. Mineralocorticoid-active precursors can accumulate while sex-steroid production is impaired. In a patient with testes, fetal AMH can still explain an absent uterus. [10]
One relevant precursor is deoxycorticosterone (DOC). Excess DOC can retain sodium, raise blood pressure and promote potassium loss. The resulting volume-related feedback suppresses renin. Thus, low sex steroids together with hypertension and hypokalemia can lead to a prediction of increased DOC and suppressed renin, not an assumption of salt wasting. This pattern is not present to the same degree in every affected patient. [22]
Use the whole pattern: hormone synthesis, hormone action, anatomy, and stability. A high testosterone concentration with little androgen effect suggests a different problem from low testosterone with mineralocorticoid effects. A blood-pressure and electrolyte pattern can therefore be more discriminating than a superficial resemblance in external anatomy.
Stabilization and nonurgent decisions belong on different timelines. Medical emergencies require immediate care. Genital procedures, disclosure, fertility discussions, and long-term treatment require informed, respectful, diagnosis-specific planning with an experienced multidisciplinary team. An educational classification should never replace the person's participation in that care. [12]
Predict: does a uterus make neonatal adrenal crisis unlikely?
No. A uterus can be present in a 46,XX infant with severe 21-hydroxylase deficiency. Internal anatomy does not protect against cortisol and mineralocorticoid deficiency. Assess the newborn's circulation, glucose, and electrolytes promptly. [9]
Build a diagnosis from the combined evidence
A short vagina and absent uterine body are a starting point, not a diagnosis. MRKH often combines Mullerian underdevelopment with functioning ovaries and a 46,XX karyotype. Complete AIS generally combines testes, effective fetal AMH action, a 46,XY karyotype, and impaired androgen response. SRD5A2 deficiency involves testes with impaired DHT formation but preserved androgen reception. [1][4]
Before treating an imaging statement as definitive, distinguish not visualized from confirmed absent. A small hypoestrogenic uterus or technically limited scan can be misleading. Reliable anatomy and appropriately interpreted testosterone testing help separate these possibilities. Hair distribution can contribute, but should not overrule stronger combined evidence.
Then ask what the diagnosis changes. Complete 46,XY gonadal dysgenesis raises a diagnosis-specific dysgenetic gonadal tumor concern and usually requires hormone replacement. CAIS involves a different gonadal context. Gonadal management should not be copied from one condition solely because both have a 46,XY karyotype. [1][5]
For confirmed complete 46,XY gonadal dysgenesis, specialist care generally includes gonadectomy at diagnosis because of dysgenetic gonadal tumor risk, even without a visible mass. These gonads are also providing inadequate pubertal steroids. Complete AIS has a different balance: functioning testes can support spontaneous estrogen effects, and informed options may include retaining them through puberty with an agreed specialist follow-up plan. [1][2][5][18]
In CAIS, an experienced team discusses gonadal risks, uncertainty, options, pubertal development, future hormone needs, and the patient's preferences. Gonadectomy removes a steroid source and substrate for estrogen formation. Hormone replacement after removal is therefore a physiological issue even though androgen receptors were already nonfunctional. [1]
Puberty induction replaces a gradual developmental process. When endogenous estrogen is inadequate, specialists generally introduce estrogen progressively rather than starting with a full adult combined regimen. If responsive uterine tissue is present, progestogen is added at an appropriate later stage to manage the estrogen-exposed endometrium. Bleeding, maturation and treatment duration help determine timing; replacement does not create ovarian follicles or reverse the underlying gonadal diagnosis. [18]
Inheritance questions need the same precision. AR-related AIS usually follows an X-linked pattern. SRD5A2 deficiency usually follows an autosomal recessive pattern. Decide whether the question already specifies the fetus's karyotype before adding another sex-chromosome probability. Transmission of a variant and the clinical expression of that variant are related but distinct questions. [2][3]
Try a transfer: testes, typical androgen effects, and a uterus. Which pathway should you inspect?
Inspect AMH production and AMH-receptor signaling. Preserved androgen effects with retained Mullerian structures suggests that the AMH pathway, rather than the androgen pathway, may be affected. Confirm the full clinical picture rather than assigning a diagnosis from the diagram alone. [6]
For inheritance questions, establish phase before calculating risk. Two variants on the same chromosome are in cis; variants on opposite homologues are in trans. A linked marker can update risk only when the family establishes which marker travels with the variant and the question supplies the recombination probability. A known fetal karyotype is a condition already given, not another probability to multiply.
Predict the answer before opening the choices. Each option has its own explanation. These original educational cases simplify selected relationships; real care requires the full clinical context.
Case 1
Show answer and explanations for case 1
A. DHT response impaired; estradiol response preserved (Best answer)
The pattern favors impaired androgen reception rather than absent DHT supply. Estrogen-responsive tissue function is preserved, so supplied estradiol should activate that reporter. Rule: Localize each hormone response independently.
B. DHT response preserved; estradiol response preserved (Why this does not fit)
Preserved estradiol response fits the spontaneous breast development. DHT is already available without the expected androgen effects. A simple DHT supply defect is not the best explanation. Rule: Adding ligand does not bypass receptor resistance.
C. DHT response preserved; estradiol response impaired (Why this does not fit)
Preserved response to DHT does not best fit available DHT with absent androgen effects. Impaired estradiol response conflicts with spontaneous breast development. Rule: A paired prediction must fit both observed target responses.
D. DHT response impaired; estradiol response impaired (Why this does not fit)
The androgen-response pattern supports an impaired DHT response. Spontaneous breast development demonstrates estrogen action. Rule: Androgen resistance does not establish estrogen resistance.
Takeaway: Available androgens do not establish androgen response; estrogen response must be assessed separately.
The testes can produce testosterone after stimulation. The downstream response works when conversion is bypassed. Rule: Low product with available substrate and intact product response localizes a conversion defect.
B. Complete androgen-receptor dysfunction (Why this does not fit)
Androgen-dependent tissues require a functioning receptor. Direct DHT activates the assay. Rule: A successful bypass response argues against complete failure of the downstream receptor pathway.
C. Reduced AMH-receptor signaling (Why this does not fit)
AMH-receptor failure can preserve Mullerian structures despite functioning testes. The uterus is absent, and the measured deficit concerns DHT formation with a preserved response to supplied DHT. Rule: A Mullerian-signaling defect does not explain an isolated testosterone-to-DHT conversion pattern.
D. Reduced 17β-hydroxysteroid dehydrogenase 3 activity (Why this does not fit)
HSD17B3 deficiency reduces testicular testosterone formation from androstenedione. Stimulated testosterone is preserved while DHT remains low. Rule: Localize the enzyme defect using the measured substrate and product.
Takeaway: A normal response to supplied DHT separates impaired conversion from receptor resistance.
A. Impaired Sertoli-cell AMH production (Best answer)
Effective androgen action supports external masculinization. Insufficient Sertoli-cell AMH failed to drive Müllerian regression. Rule: Use hormone concentration to separate ligand deficiency from receptor resistance.
B. Global failure of testicular differentiation (Why this does not fit)
Absent functional Sertoli cells would remove fetal AMH action. Testes and androgen-dependent external development are present. Rule: A selective pathway defect fits preserved functions better than global gonadal failure.
C. Primary Leydig-cell testosterone failure (Why this does not fit)
Leydig-cell testosterone failure would reduce androgen-dependent masculinization. External masculinization and testosterone are preserved. Rule: Retained Müllerian structures require evaluation of AMH action separately from testosterone.
D. AMHR2 resistance with preserved AMH secretion (Why this does not fit)
Müllerian tissue can persist when it cannot respond to AMH. AMH itself is repeatedly low for age. Rule: A production deficit is favored when the relevant ligand is lacking.
Takeaway: Androgen-driven masculinization and AMH-driven Müllerian regression are separate pathways.
A. Loss of SRD5A2 conversion activity (Why this does not fit)
SRD5A2 supports conversion of testosterone to DHT. The hormone-transfer experiment tests AMH action, not DHT formation. Rule: Match an experimental failure to the pathway actually being stimulated.
B. Loss of AMH synthesis (Why this does not fit)
Without effective fetal AMH, Mullerian structures can persist. The child's AMH activates control tissue, and replacing the hormone does not restore the child's tissue response. Rule: Active ligand plus failed replacement points beyond production.
C. Loss of androgen-receptor function (Why this does not fit)
Testosterone and DHT act through androgen receptors in androgen-responsive tissues. The observed failure is AMH-specific, and typical external masculinization supports effective androgen action. Rule: AMH and androgens do not share a receptor.
D. Loss of AMH-receptor function (Best answer)
The child's tissue does not respond to either AMH preparation, while the child's hormone activates control tissue. Loss of AMH-receptor function fits target resistance despite a biologically active ligand. Rule: Identify whether failure follows the hormone or the responding tissue.
Takeaway: Reciprocal hormone-transfer testing separates an effective ligand from an unresponsive target.
A. Arrange prompt specialist gonadectomy and a separate hormone-replacement plan (Best answer)
The gonads are not providing adequate pubertal steroid production; the pattern is not functioning testes with isolated androgen resistance. Complete 46,XY gonadal dysgenesis generally warrants gonadectomy at diagnosis because of gonadal tumor risk. Rule: Preventive gonadal-risk management does not require a visible tumor.
B. Give estrogen and reconsider the gonads only after withdrawal bleeding (Why this does not fit)
Estrogen can induce pubertal and uterine effects when gonadal steroid production is inadequate. Endometrial response does not determine the tumor risk of dysgenetic gonads. Rule: Plan hormone replacement and gonadal-risk management as separate needs.
C. Use annual pelvic imaging and intervene only if a mass appears (Why this does not fit)
No mass is currently detected, and imaging can document anatomy. The gonadal-dysgenesis recommendation addresses risk before a tumor is detected. Rule: Negative imaging does not replace diagnosis-specific preventive management.
D. Retain the gonads until spontaneous puberty is completed (Why this does not fit)
Functioning testes in complete androgen insensitivity can support spontaneous estrogen effects. These dysgenetic gonads provide inadequate steroids and have a different tumor-risk context. Rule: Do not transfer the CAIS puberty rationale to complete gonadal dysgenesis.
Takeaway: The absence of a mass does not remove the tumor-risk implication of complete 46,XY gonadal dysgenesis.
A has testosterone and DHT available without the expected androgen effects. B retains testosterone-associated pubertal effects while DHT formation is disproportionately low. Rule: Both ligand availability and target response must fit each patient.
B. A: impaired DHT formation; B: impaired androgen response (Why this does not fit)
DHT is available in A despite absent androgen effects. B has retained pubertal androgen effects with disproportionately low DHT. Rule: Test each half of a paired mechanism against its own evidence.
C. A: impaired androgen response; B: impaired androgen response (Why this does not fit)
Impaired androgen response fits A despite available testosterone and DHT. B has pubertal androgen effects and selectively poor DHT formation, favoring a conversion defect. Rule: Similar anatomy at birth does not imply the same pubertal mechanism.
D. A: impaired DHT formation; B: impaired DHT formation (Why this does not fit)
Impaired DHT formation with retained testosterone action fits B. A has DHT within the pubertal range but lacks expected androgen effects. Rule: A conversion defect cannot by itself explain resistance to available ligand.
Takeaway: One patient cannot decide a comparison when both mechanisms must be inferred.
A. Impaired 21-hydroxylation; increased gonadotropins (Why this does not fit)
21-hydroxylase deficiency can produce androgen excess and virilization. Normal repeated 17-hydroxyprogesterone and cortisol reserve, together with pregnancy-limited maternal virilization, favor impaired aromatization. Rule: The steroid profile and maternal history must fit the proposed source.
B. Impaired testosterone-to-estradiol conversion; decreased gonadotropins (Why this does not fit)
Aromatase deficiency can connect maternal virilization during pregnancy with absent estrogen-driven puberty in the daughter. Loss of estrogen feedback does not by itself explain suppressed central stimulation. Rule: Separate deficient steroid formation from deficient central drive.
C. Impaired 21-hydroxylation; decreased gonadotropins (Why this does not fit)
An adrenal 21-hydroxylase defect can cause androgen excess, but the supplied adrenal evaluation does not support it. The case favors inadequate estrogen production rather than primary loss of gonadotropin drive. Rule: Identify the source of excess androgen and the direction of estrogen feedback separately.
D. Impaired testosterone-to-estradiol conversion; increased gonadotropins (Best answer)
Aromatase deficiency can impair placental androgen-to-estrogen conversion and the daughter's later ovarian estrogen formation. Inadequate estrogen feedback permits increased gonadotropin drive. Rule: A functioning ovary still needs aromatase to turn androgen substrate into estrogen.
Takeaway: Aromatase loss links failed placental androgen disposal to inadequate pubertal estrogen feedback.
A. Response to supplied DHT preserved; prostate development more impaired (Best answer)
Preserved testosterone-associated virilization with deficient DHT formation favors a conversion defect rather than complete androgen resistance. Supplied DHT can act through the retained receptor, while deficient fetal DHT can impair prostate development more than testosterone-supported Wolffian derivatives. Rule: A conversion defect can be bypassed without changing which developmental tissues required its product.
B. Response to supplied DHT preserved; Wolffian development more impaired (Why this does not fit)
Direct hormone provision can bypass impaired formation when androgen reception is retained. Testosterone supports Wolffian development, whereas prostate development is more DHT-dependent. Rule: Identify the hormone needed by each target before predicting anatomy.
C. Response to supplied DHT impaired; prostate development more impaired (Why this does not fit)
The prostate depends strongly on DHT during development, so the low-product pattern supports that prediction. The observed testosterone-associated virilization favors retained androgen reception rather than complete resistance. Rule: Distinguish an unavailable product from a target that cannot respond to it.
D. Response to supplied DHT impaired; Wolffian development more impaired (Why this does not fit)
Voice deepening and phallic growth show androgen effects despite low DHT formation. Wolffian derivatives rely on testosterone action and need not be the more impaired compartment in this conversion disorder. Rule: The enzyme defect and target dependency must both fit the prediction.
Takeaway: Localize deficient DHT formation, then predict bypass responsiveness and tissue-specific development.
A. Ratio equals 3.6 and is quantified; repeat the same unstimulated low-range assay (Why this does not fit)
Substituting the quantification limit treats an unknown value as a measurement. Low prepubertal secretion may still prevent an informative pair on the same basal assay. Rule: Correct both the numerical interpretation and the testing conditions.
B. Ratio exceeds 3.6 but is not quantified; obtain an interpretable hCG-stimulated steroid pair (Best answer)
For testosterone fixed at 18 and a positive DHT below 5, the ratio exceeds 3.6 but its exact value is unknown. Prepubertal basal secretion may be too low for reliable paired interpretation; appropriate hCG stimulation and quantitative assays can improve assessment. Rule: A bound is not a measured ratio, and low basal secretion may require a different testing condition.
C. Ratio equals 3.6 and is quantified; obtain an interpretable hCG-stimulated steroid pair (Why this does not fit)
An appropriately interpreted stimulated testosterone and DHT pair can help evaluate testicular steroid function. The laboratory reported a quantification boundary rather than a DHT value of 5. Rule: A sound next test does not turn an unmeasured denominator into an exact number.
D. Ratio exceeds 3.6 but is not quantified; repeat the same unstimulated low-range assay (Why this does not fit)
The ratio exceeds 3.6, a strict lower bound, but its exact value is unknown. The same low basal secretion and assay limit can leave the denominator unquantified again. Rule: Choose conditions that address the identified limitation rather than only repeating it.
Takeaway: Interpret an assay bound before choosing how to obtain an informative hormone pair.
A. Cervicovaginal outflow canalization (Why this does not fit)
A distal barrier can cause amenorrhea despite ovarian function. Imaging shows tract underdevelopment rather than a formed endometrial cavity behind a barrier. Rule: Obstruction requires a developed proximal tract to obstruct.
B. Hypothalamic gonadotropin stimulation (Why this does not fit)
Inadequate gonadotropins can limit ovarian estrogen production. Estrogen effect is present and MRI identifies structural upper-tract underdevelopment. Rule: A structural finding should not be attributed solely to endocrine suppression.
C. Müllerian tract development (Best answer)
Ovarian endocrine function is present. The uterus and upper vagina are underdeveloped. Rule: Separate ovarian function from Müllerian anatomy.
D. Ovarian follicle development (Why this does not fit)
Ovarian failure could reduce estrogen-driven pubertal development. Follicular ovaries, pubertal estradiol, and breasts are present. Rule: Preserved endocrine findings shift attention toward anatomy.
Takeaway: Preserved ovarian function can coexist with Müllerian tract underdevelopment.
A. Both FSH and LH increase substantially (Why this does not fit)
FSH is expected to increase as inhibin B feedback falls. Leydig steroid output and the measured circulating steroid feedback remain near baseline. Rule: A selective tubular lesion is not automatically global testicular failure.
B. FSH remains near its previous level; LH increases (Why this does not fit)
The low inhibin B primarily supports a compensatory FSH increase. The stipulated stable testosterone and estradiol do not support loss of steroid feedback. Rule: Do not exchange the Sertoli-associated and steroid-feedback pathways.
C. Both FSH and LH decrease substantially (Why this does not fit)
Reduced central stimulation or stronger feedback could suppress both signals. There is no central injury or added hormone, and inhibin B feedback has decreased. Rule: Reduced peripheral feedback permits compensation rather than proving central suppression.
D. FSH increases; LH remains near its previous level (Best answer)
Low inhibin B after seminiferous injury reduces gonadal restraint of FSH. The circulating steroid feedback relevant to LH remains near baseline. Rule: Compare each gonadotropin with the feedback signal that actually changed.
Takeaway: Loss of one gonadal feedback signal need not remove the other.
A. Both FSH and LH decrease toward their normal ranges (Why this does not fit)
The intervention restores the inhibin signal that restrains FSH. Low Leydig steroid production persists, so both feedback deficits have not been corrected. Rule: A partial rescue is not global endocrine recovery.
B. FSH decreases; LH remains elevated (Best answer)
Restored inhibin increases restraint of FSH, so FSH should decrease in the model. Leydig steroid output remains low, leaving the principal LH feedback deficit unresolved. Rule: Correcting one testicular compartment does not correct both feedback pathways.
C. Both FSH and LH remain at their initial elevated levels (Why this does not fit)
Restored Sertoli-associated inhibin supplies feedback that was missing in the initial model. FSH should decrease even though the low-steroid signal driving LH has not been corrected. Rule: A selective rescue changes its own downstream feedback response.
D. FSH remains elevated; LH decreases (Why this does not fit)
Sertoli-associated inhibin secretion, not Leydig testosterone production, is restored. FSH should decrease with restored inhibin feedback. Rule: Match the corrected compartment to its feedback target.
Takeaway: Restoring Sertoli feedback does not repair a persisting Leydig-cell deficit.
A. FSH decreases; the uterine endometrium can proliferate (Best answer)
Administered estradiol restores part of the negative feedback that was missing, so the pituitary signal can decrease. The retained uterine endometrium can respond to estrogen, making later progestogen planning relevant. Rule: Replacement can change feedback and target tissue without repairing the ovary.
B. FSH increases; the uterine endometrium can proliferate (Why this does not fit)
The ultrasound establishes a uterus that can respond to administered estrogen. Restored estrogen feedback tends to reduce, not further increase, the compensatory FSH elevation. Rule: Follow the direction of negative feedback before interpreting a follow-up value.
C. FSH increases; the uterine endometrium remains estrogen-unresponsive (Why this does not fit)
Insufficient gonadal steroid feedback allowed compensatory pituitary stimulation. Estradiol can restrain that signal and act on the retained endometrium. Rule: Gonadal failure is distinct from failure of every hormone-responsive target.
D. FSH decreases; the uterine endometrium remains estrogen-unresponsive (Why this does not fit)
Exogenous estrogen can reduce compensatory FSH secretion. A retained uterus can respond to estrogen despite ovarian insufficiency. Rule: Chromosome findings do not erase an existing target tissue's hormone response.
Takeaway: Distinguish hormone replacement effects from endogenous gonadal recovery.
A. Intravenous dexamethasone, intravenous 0.9% saline, and intravenous dextrose (Why this does not fit)
Dexamethasone supplies glucocorticoid activity and can be a fallback when preferred glucocorticoids are unavailable. Hydrocortisone is available and is the preferred emergency glucocorticoid; dexamethasone is the least-preferred alternative and lacks mineralocorticoid activity. Rule: Use available hydrocortisone for suspected pediatric adrenal crisis.
B. Intravenous hydrocortisone, intravenous 0.45% saline, and intravenous dextrose (Why this does not fit)
A clinician may associate hypotonic solutions with selected maintenance-fluid calculations rather than initial resuscitation. Shock and severe sodium depletion call for isotonic resuscitation with reassessment, not a hypotonic initial bolus. Rule: Choose the initial fluid for the circulation and electrolyte deficit, then monitor correction.
C. Intravenous hydrocortisone, intravenous 0.9% saline, and intravenous dextrose (Best answer)
Hypotension and severe hypoglycemia require prompt volume and glucose support. The hyponatremia, hyperkalemia and atypical genital development support suspected salt-wasting adrenal crisis and immediate hydrocortisone, with ongoing monitored potassium treatment and sodium correction. Rule: Treat cortisol deficiency and the concurrent physiologic threats together.
D. Oral fludrocortisone, intravenous 0.9% saline, and intravenous dextrose (Why this does not fit)
Hyponatremia and hyperkalemia raise concern for mineralocorticoid deficiency, for which fludrocortisone can be part of ongoing replacement. Suspected adrenal crisis also needs immediate parenteral glucocorticoid replacement; oral fludrocortisone does not replace that emergency treatment. Rule: Salt-wasting treatment must also address the cortisol deficit.
Takeaway: Suspected adrenal crisis requires prompt hydrocortisone and resuscitation.
A. Deoxycorticosterone decreased; renin suppressed (Why this does not fit)
Renin suppression fits a sodium-retaining state. Low sex steroids with hypertension and hypokalemia favors accumulation of a mineralocorticoid-active precursor, not loss of that precursor. Rule: The biochemical block must explain both synthesis and feedback.
B. Deoxycorticosterone increased; renin increased (Why this does not fit)
Increased deoxycorticosterone can explain hypertension and potassium loss. Sodium retention and volume expansion suppress, rather than drive, renin in this model. Rule: Apply feedback after identifying the accumulating precursor.
C. Deoxycorticosterone increased; renin suppressed (Best answer)
A 17-alpha-hydroxylase/17,20-lyase defect can increase deoxycorticosterone while limiting sex-steroid formation. Volume-related feedback suppresses renin. Rule: Mineralocorticoid effects do not require increased renin or primary aldosterone production.
D. Deoxycorticosterone decreased; renin increased (Why this does not fit)
Deficient mineralocorticoid effect with salt loss can provoke compensatory renin elevation. This patient has hypertension and potassium loss, supporting mineralocorticoid excess. Rule: Distinguish salt wasting from precursor-driven sodium retention.
Takeaway: Mineralocorticoid precursor excess can suppress renin while sex-steroid synthesis is deficient.
A. Functioning testes; ACTH increased (Why this does not fit)
Low cortisol from primary adrenal synthesis failure supports increased ACTH. Functioning fetal testes ordinarily supply AMH and cause Mullerian regression; the retained uterus and adrenal virilization pattern instead favor ovaries. Rule: Adrenal androgen effects do not by themselves establish testes.
B. Ovaries; ACTH decreased (Why this does not fit)
Ovarian development with adrenal androgen excess fits the most likely 46,XX CAH presentation. Inadequate cortisol feedback permits increased ACTH rather than suppressing it. Rule: Primary adrenal synthesis failure and central ACTH deficiency predict different feedback responses.
C. Ovaries; ACTH increased (Best answer)
Classic 21-hydroxylase deficiency in a 46,XX infant can produce adrenal androgen excess while ovaries and Mullerian structures develop. Reduced cortisol feedback increases ACTH drive. Rule: Gonadal development, adrenal androgen exposure and cortisol feedback answer separate parts of this presentation.
D. Functioning testes; ACTH decreased (Why this does not fit)
Adrenal androgen excess can virilize external genitalia without a testicular AMH source. The low cortisol and high steroid precursor pattern favors a primary synthesis block with increased central drive. Rule: Both the anatomical source and feedback direction must fit.
Takeaway: Adrenal androgen excess can coexist with ovarian development, while cortisol deficiency raises ACTH drive.
A's pattern favors complete androgen insensitivity; fetal AMH can act independently and cause Mullerian regression. B's effective hormone fails on B's target tissue, supporting impaired AMH action and Mullerian persistence. Rule: Predict internal ducts from AMH action, not external appearance alone.
B. A: absent Mullerian structures; B: absent Mullerian structures (Why this does not fit)
Androgen resistance can coexist with fetal AMH-mediated Mullerian regression. B's AMH-response experiment demonstrates a target problem that prevents normal AMH action. Rule: Producing AMH does not guarantee responding to it.
C. A: retained Mullerian structures; B: retained Mullerian structures (Why this does not fit)
AMH target resistance can preserve Mullerian structures in B. A's preserved Sertoli function can supply AMH independently of androgen receptors. Rule: Androgen resistance is not equivalent to AMH resistance.
D. A: retained Mullerian structures; B: absent Mullerian structures (Why this does not fit)
AMH-mediated regression does not require functioning androgen receptors. B has evidence of AMH target resistance despite effective androgen development. Rule: Read the two fetal signaling systems separately in each patient.
Takeaway: Clinical androgen effects and functional AMH response can predict different internal anatomy despite testes in both patients.
A. DHT response is expected through product bypass; fetal androgen action accounts for Mullerian regression (Why this does not fit)
Direct DHT can bypass impaired formation when androgen reception remains functional. Mullerian regression is mediated by AMH signaling rather than androgen reception. Rule: A correct treatment-response prediction does not validate the wrong fetal pathway.
B. DHT response is limited by favored receptor failure; fetal AMH accounts for Mullerian regression (Why this does not fit)
Fetal AMH can account for Mullerian regression and an absent uterus. The preserved pubertal androgen effects and selectively poor DHT formation favor conversion impairment over complete androgen resistance. Rule: Use the supplied response history to distinguish receptor failure from product deficiency.
C. DHT response is limited by favored receptor failure; fetal androgen action accounts for Mullerian regression (Why this does not fit)
Pubertal testosterone effects with low DHT favor impaired conversion with retained response. AMH signaling controls Mullerian regression. Rule: Both the current response and the fetal anatomy need their own supported explanation.
D. DHT response is expected through product bypass; fetal AMH accounts for Mullerian regression (Best answer)
Preserved testosterone-associated pubertal effects with low DHT favors a conversion defect that direct DHT can bypass. Fetal AMH, not the current androgen concentration, accounts for Mullerian regression in this setting. Rule: Distinguish present hormone responsiveness from the pathway that established fetal anatomy.
Takeaway: A current ligand-bypass response and a completed fetal duct event answer different questions.
A. Testicular development; impaired future sperm production (Best answer)
The translocated functional SRY region can initiate testicular differentiation despite the 46,XX chromosome count. Other Y-chromosome genes support spermatogenesis and are absent from the supplied genetic result. Rule: Testis determination and production of sperm are distinct genetic functions.
B. Ovarian development; preserved future egg production (Why this does not fit)
The proposed ovarian-development prediction does not account for the translocated functional testis-determining region. SRY-associated testicular development does not imply ovaries or normal egg production. Rule: Determine the developmental pathway before predicting reproductive function.
C. Ovarian development; impaired future egg production (Why this does not fit)
Most 46,XX development follows an ovarian pathway when a testis-determining signal is absent. Functional SRY is present on an X chromosome and can initiate testicular differentiation. Rule: Interpret relevant gene content rather than the chromosome count alone.
D. Testicular development; preserved future sperm production (Why this does not fit)
The functional translocated SRY region can initiate that developmental pathway. The remaining Y-chromosome material needed for normal spermatogenesis is absent. Rule: A gonad can form without having every requirement for its later reproductive function.
Takeaway: Separate testis determination from the additional genetic requirements of spermatogenesis.
The 50% answer ignores the marker information: the maternal AR variant is on the M-bearing chromosome, as established from the normal paternal m-bearing copy. The stipulated 10% recombination fraction makes marker M informative about AR inheritance. Rule: Use linkage information after resolving the transmitted parental haplotype.
B. 45% (Why this does not fit)
The question already conditions on a 46,XY fetus that inherited marker M. The relevant conditional probability is nonrecombination after M inheritance, not the unconditioned chance of transmitting the entire haplotype. Rule: Do not multiply again for an event already established.
C. 10% (Why this does not fit)
Her father supplied a normal AR copy with marker m, so her variant must be on the other, M-bearing copy. The 10% recombination fraction describes separation of the linked variant from M, rather than their usual cotransmission. Rule: Establish phase before assigning the recombinant probability.
D. 90% (Best answer)
The woman's father contributed normal AR with m; therefore her variant is linked to M on the other X chromosome. The linked variant remains with M in the 90% nonrecombinant fraction. Rule: Resolve phase, then apply the conditional recombination probability.
Takeaway: Derive maternal linkage phase from family data before calculating conditional risk.
Family data place P and Q together on the chromosome the father received from his father. The father can transmit the P-Q allele and the mother can transmit R. Rule: Count affected parental alleles, not the number of variant labels.
B. 50% (Why this does not fit)
Treating P and Q as variants on opposite paternal alleles would incorrectly make every paternal transmission affected. P and Q are together on one paternal allele, so only half of paternal transmissions carry that affected allele; combining this with the mother's one-half transmission gives one-quarter. Rule: Resolve cis versus trans before multiplying parental risks.
C. 25% (Best answer)
Because the paternal grandmother carries neither variant, P and Q are on the same paternal-grandfather-derived allele in the father; his other allele is normal. One-half transmission of P-Q multiplied by one-half transmission of R gives one-quarter. Rule: Determine phase before applying the recessive inheritance calculation.
D. 75% (Why this does not fit)
A 75% probability counts offspring receiving at least one affected parental allele, not necessarily two. The question asks for an affected allele from both parents, which is one-quarter. Rule: Distinguish at least one affected allele from biallelic inheritance.
Takeaway: Infer variant phase, then count affected alleles rather than mutation names.
A. Gradual estrogen induction without a later progestogen plan (Why this does not fit)
Gradual estrogen addresses deficient pubertal estrogen. The uterus contains endometrium that can respond to estrogen. Rule: Include endometrial protection when uterine tissue is present.
B. Progestogen induction first, followed by estrogen only if withdrawal bleeding occurs (Why this does not fit)
Estradiol is low with elevated FSH. The thin endometrium needs estrogen exposure for pubertal and uterine development. Rule: Treat the documented steroid deficit before relying on endometrial withdrawal.
C. Gradual estrogen induction, with progestogen added at the appropriate later stage (Best answer)
Low estradiol with high FSH supports estrogen replacement for pubertal induction. An estrogen-responsive endometrium makes later progestogen relevant. Rule: Plan hormone components from functioning tissue, not karyotype alone.
D. Immediate full-dose combined estrogen and progestogen from the start of induction (Why this does not fit)
Puberty should be induced gradually with estrogen. Progestogen is introduced at an appropriate later stage as endometrial exposure develops. Rule: Sequence replacement according to pubertal development and uterine response.
Takeaway: Estrogen induction addresses gonadal steroid deficiency; progestogen becomes relevant when estrogen stimulates a uterus.
A. A: defer until spontaneous puberty; B: immediate gonadectomy as the required plan (Why this does not fit)
Dysgenetic gonads are not providing adequate pubertal steroids and warrant prompt risk management. The CAIS risk-benefit discussion can include retaining functioning gonads through puberty. Rule: Match both timing decisions to the actual gonadal diagnosis.
B. A: prompt gonadectomy planning; B: offer retention through puberty with specialist follow-up (Best answer)
A's dysgenetic gonads supply inadequate steroids and have a tumor-risk indication for removal at diagnosis. B's testes support spontaneous estrogen effects; diagnosis-specific counseling can support retention through puberty with agreed follow-up. Rule: A shared 46,XY context does not establish identical gonadal management.
C. A: defer until spontaneous puberty; B: offer retention through puberty with specialist follow-up (Why this does not fit)
B has functioning testes and ongoing breast development. A has inadequate steroid production and dysgenetic gonadal tumor risk. Rule: Retention for pubertal benefit requires an actual source of that benefit.
D. A: prompt gonadectomy planning; B: immediate gonadectomy as the required plan (Why this does not fit)
Prompt gonadal-risk management fits complete gonadal dysgenesis. The CAIS context includes a pubertal hormone benefit and an informed preference without a suspicious lesion. Rule: Discuss diagnosis-specific options rather than importing the dysgenesis timetable.
Takeaway: Gonadal-dysgenesis risk and CAIS pubertal hormone benefit lead to different management discussions.
A. CYP21A2 sequencing with deletion-duplication analysis and parental testing (Why this does not fit)
CYP21A2 genetic analysis can characterize a suspected 21-hydroxylase defect and inform inheritance counseling. Guidance prioritizes a stimulated steroid profile after a borderline screen; genotyping is useful when that profile is equivocal, cannot be interpreted, or for counseling. Rule: Clarify the biochemical phenotype before escalating an interpretable borderline screen to genetic confirmation.
B. Repeat early-follicular basal 17-hydroxyprogesterone measurement by LC-MS/MS (Why this does not fit)
An optimized repeat basal 17-hydroxyprogesterone test can clarify an initial result obtained at an unsuitable time or with a less-specific assay. The initial sample was correctly timed and measured by LC-MS/MS, yet remains borderline. Rule: A valid borderline screen calls for dynamic clarification rather than simply repeating the same stage.
C. Cosyntropin stimulation with a complete adrenocortical steroid profile (Best answer)
A correctly obtained borderline 17-hydroxyprogesterone keeps nonclassic 21-hydroxylase deficiency possible without confirming it. A cosyntropin-stimulated steroid profile assesses the adrenocortical response pattern and helps distinguish 21-hydroxylase deficiency from other steroidogenic defects. Rule: Confirm a borderline steroid screen with an appropriate dynamic profile.
D. Pelvic ultrasonography with assessment of ovarian morphology and volume (Why this does not fit)
Chronic hirsutism and infrequent cycles can occur with an ovarian ovulatory disorder. Ovarian morphology cannot resolve the borderline adrenal precursor result or establish a partial adrenal enzyme defect. Rule: Investigate the biochemical uncertainty that distinguishes the competing causes.
Takeaway: A borderline 17-hydroxyprogesterone screen calls for an interpreted cosyntropin-stimulated steroid profile.
A. Loss of testicular testosterone substrate for aromatization (Best answer)
Removal of the testes reduced endogenous testosterone supply. Less testosterone was available for aromatization. Rule: Receptor resistance does not prevent androgen substrate from becoming estrogen.
B. Loss of adrenal DHEAS substrate for aromatization (Why this does not fit)
Adrenal precursors can contribute to estrogen formation. DHEAS remains near baseline while testosterone and estradiol fall. Rule: Link a postoperative product change to the source that actually changed.
C. New failure of peripheral aromatase activity (Why this does not fit)
Peripheral aromatase failure could reduce estrogen formation from androgen substrate. Testosterone substrate fell after gonad removal; no aromatase change is supplied. Rule: Check substrate loss before inferring a new enzyme defect.
D. Loss of ovarian follicular estradiol secretion (Why this does not fit)
Functioning follicles can secrete estradiol. The patient has complete AIS and the removed gonads were testes. Rule: Attribute hormone changes to the tissue actually present and removed.
Takeaway: Removing testes removes a major testosterone substrate for aromatized estrogen.
